Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › FDA Approves Myriad Genetics' BRACAnalysis CDx With Lynparza in Earlier Ovarian Cancer Setting

FDA Approves Myriad Genetics' BRACAnalysis CDx With Lynparza in Earlier Ovarian Cancer Setting

Dec 19, 2018
|
staff reporter

NEW YORK (GenomeWeb) – The US Food and Drug Administration has expanded the indication for Myriad Genetics’ BRACAnalysis CDx, allowing it to be used to identify advanced ovarian cancer patients who are eligible to receive AstraZeneca’s Lynparza (olaparib) as first-line maintenance therapy after responding to platinum-based chemotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14
Featured Webinar

Development of a Metagenomics-based Pathogen-Detection Assay for SARS-CoV-2 Research

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Molecular Diagnostics

  1. BioMérieux Reports 62 Percent BioFire FilmArray Sales Growth in Preliminary Q2 Release

  2. Amid Interest Generated by Coronavirus Testing, IPO Window Open for Dx Firms in 2020

    Premium

  3. LGC Acquires UK Infectious Disease Firm to Expand Reagent Portfolio

  4. Payor Policy Study Reveals Progress, Challenges in Liquid Biopsy Reimbursement

  5. Quest Study Finds Cotesting Outperforms HPV Test in Detecting Cervical Cancer

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.